New Contract Win

RNS Number : 8126I

IXICO plc

21 April 2022

 

21 April 2022

IXICO plc

("IXICO" or the "Company")

Contract award with a new client for a Huntington's Disease ('HD') trial worth circa £800,000

IXICO plc (AIM: IXI), the neuroimaging Contract Research Organisation (CRO) delivering advanced AI analytical insights in neuroscience, is pleased to announce it has been selected by a new client to support its global prospective observational study to assess participants for the early detection of HD.  HD is a rare, inherited disease that causes the progressive breakdown of nerve cells in the brain affecting movement, mood and thinking abilities.

The new client is a biotech company specialized in gene therapy for neurodegenerative and other genetic diseases. IXICO will provide a range of its imaging CRO and advanced analytics services across approximately 2.5 years.  

Having combined AI imaging biomarker analysis across many HD trials, together with centralised CRO services, IXICO is continuously enhancing its validated disease-optimised advanced analytics technology for this indication.  This new contract follows our recent presentation on our new deep learning-based platform, IXIQ.Ai, at the Annual HD Therapeutics Conference in Palm Springs, a technology which IXICO will be applying to this trial.  This, together with the ability to deliver its services through our proprietary TrialTracker imaging data management platform, makes IXICO the clear partner of choice for this study.

Giulio Cerroni, Chief Executive Officer of IXICO, commented : " With no current cure for Huntington's, nor interventions that slow disease progression, HD is a devastating rare neurological condition with significant unmet medical needs. We are delighted to further extend our client base and support identifying new insights into this challenging rare neurodegenerative disease. We are committed to ensuring that our validated machine learning AI data analytics, combined with the quality assurance of our TrialTracker platform, enable clients to unlock new insights into disease progression and drug development."

For further information please contact:

IXICO plc			[phone]
Giulio Cerroni, Chief Executive Officer Grant Nash, Chief Financial Officer
Cenkos Securities PLC (Nominated adviser and sole broker)				[phone]
Giles Balleny / Max Gould (Corporate Finance)
Michael F Johnson / Tamar Cranford-Smith (Sales)

About IXICO | Advanced Analytics | Intelligent Insights.

IXICO is dedicated to delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Huntington's, Parkinson's, Alzheimer's disease and Multiple Sclerosis. The Company's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience by supporting pharmaceutical companies across all phases of CNS clinical research. IXICO's goal is to be a leading advocate of artificial intelligence in medical image analysis.  

IXICO has developed and deployed breakthrough machine learning Ai data analytics, at scale, through its remote access TrialTracker technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for the Company's pharmaceutical clients.

More information is available on www.IXICO.com   and follow us on Twitter @IXICOnews

 

END

 

 

CNTQBLFLLZLZBBK